Cargando…
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients
It is critical to protect immunocompromised patients against COVID-19 with effective SARS-CoV-2 vaccination as they have an increased risk of developing severe disease. This is challenging, however, since effective mRNA vaccination requires the successful cooperation of several components of the inn...
Autores principales: | Baron, Frédéric, Canti, Lorenzo, Ariën, Kevin K., Kemlin, Delphine, Desombere, Isabelle, Gerbaux, Margaux, Pannus, Pieter, Beguin, Yves, Marchant, Arnaud, Humblet-Baron, Stéphanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931657/ https://www.ncbi.nlm.nih.gov/pubmed/35309332 http://dx.doi.org/10.3389/fimmu.2022.827242 |
Ejemplares similares
-
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
por: Canti, Lorenzo, et al.
Publicado: (2022) -
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
por: Canti, Lorenzo, et al.
Publicado: (2021) -
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
por: Pannus, Pieter, et al.
Publicado: (2022) -
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
por: Kemlin, Delphine, et al.
Publicado: (2023) -
Validation of a multicolor staining to monitor (phospho)STAT5 levels in regulatory T-cell subsets
por: Ehx, Grégory, et al.
Publicado: (2015)